{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T18:58:26Z","timestamp":1790535506181,"version":"4.1.0"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,12,7]],"date-time":"2022-12-07T00:00:00Z","timestamp":1670371200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,12,7]],"date-time":"2022-12-07T00:00:00Z","timestamp":1670371200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Pathological complete response (pCR) after neoadjuvant chemotherapy (NCT) is associated with good long-term prognosis in breast cancer (BC) patients. However, some patients still recur and eventually die from this disease. For years, clinical stage at diagnosis has been consistently linked to recurrence and survival in the pCR setting. Herein, we aimed to identify other potential predictors of recurrence and survival in patients that achieved pCR. We performed a retrospective analysis of patients diagnosed between 2011 and 2020 in our center. We calculated overall survival (OS), invasive disease-free survival (IDFS), distant disease-free survival (DDFS), and BC-specific survival (BCSS). Among the 241 patients included into our study 36% were obese (Body Mass Index (BMI)\u2009&gt;\u200929.9\u00a0kg\/m<jats:sup>2<\/jats:sup>) and 47% were stage III. Multivariate analysis confirmed that obesity was a significant risk factor associated with early recurrence and poorer survival in these patients. In summary, obesity and clinical stage predict early recurrence and poorer survival in patients that achieved pCR after NCT. Pending further investigation and based on our findings we speculate that weight management could be beneficial for this subset of patients. To our knowledge, this is the first Latin American report linking obesity and recurrence within this setting.<\/jats:p>","DOI":"10.1038\/s41598-022-25043-2","type":"journal-article","created":{"date-parts":[[2022,12,7]],"date-time":"2022-12-07T11:09:59Z","timestamp":1670411399000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["Obesity is associated with early recurrence on breast cancer patients that achieved pathological complete response to neoadjuvant chemotherapy"],"prefix":"10.1038","volume":"12","author":[{"given":"Francisco","family":"Acevedo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjam\u00edn","family":"Walbaum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabrina","family":"Mu\u00f1iz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Militza","family":"Petric","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ra\u00fal","family":"Mart\u00ednez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Constanza","family":"Guerra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marisel","family":"Navarro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miguel","family":"C\u00f3rdova-Delgado","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mauricio P.","family":"Pinto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cesar","family":"S\u00e1nchez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,12,7]]},"reference":[{"key":"25043_CR1","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3322\/caac.21654","volume":"71","author":"RL Siegel","year":"2021","unstructured":"Siegel, R. L., Miller, K. D., Fuchs, H. E. & Jemal, A. Cancer statistics, 2021. CA. Cancer J. Clin. 71, 7\u201333 (2021).","journal-title":"CA. Cancer J. Clin."},{"key":"25043_CR2","doi-asserted-by":"publisher","first-page":"1005","DOI":"10.3332\/ecancer.2020.1005","volume":"14","author":"C Maiz","year":"2020","unstructured":"Maiz, C. et al. Mammography correlates to better survival rates in breast cancer patients: A 20-year experience in a University health institution. Ecancermedicalscience 14, 1005 (2020).","journal-title":"Ecancermedicalscience"},{"key":"25043_CR3","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.breast.2022.08.010","volume":"66","author":"M Arnold","year":"2022","unstructured":"Arnold, M. et al. Current and future burden of breast cancer: Global statistics for 2020 and 2040. Breast 66, 15\u201323 (2022).","journal-title":"Breast"},{"key":"25043_CR4","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/S1470-2045(17)30777-5","volume":"19","author":"B Asselain","year":"2018","unstructured":"Asselain, B. et al. Long-term outcomes for neoadjuvant versus adjuvant chemotherapy in early breast cancer: Meta-analysis of individual patient data from ten randomised trials. Lancet Oncol. 19, 27\u201339 (2018).","journal-title":"Lancet Oncol."},{"key":"25043_CR5","doi-asserted-by":"publisher","first-page":"1185","DOI":"10.3332\/ecancer.2021.1185","volume":"15","author":"F Acevedo","year":"2021","unstructured":"Acevedo, F. et al. Better overall survival in patients who achieve pathological complete response after neoadjuvant chemotherapy for breast cancer in a Chilean public hospital. Ecancermedicalscience 15, 1185 (2021).","journal-title":"Ecancermedicalscience"},{"key":"25043_CR6","doi-asserted-by":"publisher","first-page":"2147","DOI":"10.1056\/NEJMoa1612645","volume":"376","author":"N Masuda","year":"2017","unstructured":"Masuda, N. et al. Adjuvant capecitabine for breast cancer after preoperative chemotherapy. N. Engl. J. Med. 376, 2147\u20132159 (2017).","journal-title":"N. Engl. J. Med."},{"key":"25043_CR7","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1200\/JCO.19.00904","volume":"38","author":"A Lluch","year":"2020","unstructured":"Lluch, A. et al. Phase III trial of adjuvant capecitabine after standard neo-\/adjuvant chemotherapy in patients with early triple-negative breast cancer (GEICAM\/2003-11_CIBOMA\/2004-01). J. Clin. Oncol. 38, 203\u2013213 (2020).","journal-title":"J. Clin. Oncol."},{"key":"25043_CR8","doi-asserted-by":"publisher","first-page":"2838","DOI":"10.1158\/1078-0432.CCR-19-3492","volume":"26","author":"LM Spring","year":"2020","unstructured":"Spring, L. M. et al. Pathologic complete response after neoadjuvant chemotherapy and impact on breast cancer recurrence and survival: A comprehensive meta-analysis. Clin. Cancer Res. 26, 2838\u20132848 (2020).","journal-title":"Clin. Cancer Res."},{"key":"25043_CR9","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1001\/jamaoncol.2015.6113","volume":"2","author":"KR Broglio","year":"2016","unstructured":"Broglio, K. R. et al. Association of pathologic complete response to neoadjuvant therapy in HER2-positive breast cancer with long-term outcomes ameta-analysis. JAMA Oncol. 2, 751\u2013760 (2016).","journal-title":"JAMA Oncol."},{"key":"25043_CR10","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0234191","volume":"15","author":"AS Hamy","year":"2020","unstructured":"Hamy, A. S. et al. Prognostic value of the residual cancer burden index according to breast cancer subtype: Validation on a cohort of bc patients treated by neoadjuvant chemotherapy. PLoS ONE 15, e0234191 (2020).","journal-title":"PLoS ONE"},{"key":"25043_CR11","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1016\/j.ejca.2014.11.023","volume":"51","author":"F Fei","year":"2015","unstructured":"Fei, F. et al. Tumour size is the only predictive factor of distant recurrence after pathological complete response to neoadjuvant chemotherapy in patients with large operable or locally advanced breast cancers: A sub-study of EORTC 10994\/BIG 1\u201300 phase III trial. Eur. J. Cancer 51, 301\u2013309 (2015).","journal-title":"Eur. J. Cancer"},{"key":"25043_CR12","doi-asserted-by":"publisher","first-page":"2289","DOI":"10.1016\/j.ejso.2019.08.001","volume":"45","author":"M Asaoka","year":"2019","unstructured":"Asaoka, M. et al. Clinical and pathological predictors of recurrence in breast cancer patients achieving pathological complete response to neoadjuvant chemotherapy. Eur. J. Surg. Oncol. 45, 2289\u20132294 (2019).","journal-title":"Eur. J. Surg. Oncol."},{"key":"25043_CR13","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1007\/s10549-015-3533-x","volume":"153","author":"M Chaudry","year":"2015","unstructured":"Chaudry, M. et al. Recurrence and survival among breast cancer patients achieving a pathological complete response to neoadjuvant chemotherapy. Breast Cancer Res. Treat. 153, 417\u2013423 (2015).","journal-title":"Breast Cancer Res. Treat."},{"key":"25043_CR14","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1007\/s10549-007-9785-3","volume":"111","author":"B Majed","year":"2008","unstructured":"Majed, B. et al. Is obesity an independent prognosis factor in woman breast cancer?. Breast Cancer Res. Treat. 111, 329\u2013342 (2008).","journal-title":"Breast Cancer Res. Treat."},{"key":"25043_CR15","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1007\/s10549-009-0708-3","volume":"122","author":"X Chen","year":"2010","unstructured":"Chen, X. et al. Obesity and weight change in relation to breast cancer survival. Breast Cancer Res. Treat. 122, 823\u2013833 (2010).","journal-title":"Breast Cancer Res. Treat."},{"key":"25043_CR16","doi-asserted-by":"publisher","first-page":"3411","DOI":"10.1200\/JCO.2009.27.2021","volume":"28","author":"I Sestak","year":"2010","unstructured":"Sestak, I. et al. Effect of body mass index on recurrences in tamoxifen and anastrozole treated women: An exploratory analysis from the ATAC trial. J. Clin. Oncol. 28, 3411\u20133415 (2010).","journal-title":"J. Clin. Oncol."},{"key":"25043_CR17","doi-asserted-by":"publisher","first-page":"3967","DOI":"10.1200\/JCO.2011.40.8666","volume":"30","author":"M Ewertz","year":"2012","unstructured":"Ewertz, M. et al. Obesity and risk of recurrence or death after adjuvant endocrine therapy with letrozole or tamoxifen in the breast international group 1\u201398 trial. J. Clin. Oncol. 30, 3967\u20133975 (2012).","journal-title":"J. Clin. Oncol."},{"key":"25043_CR18","doi-asserted-by":"publisher","first-page":"1901","DOI":"10.1093\/annonc\/mdu042","volume":"25","author":"DSM Chan","year":"2014","unstructured":"Chan, D. S. M. et al. Body mass index and survival in women with breast cancer\u2014Systematic literature review and meta-analysis of 82 follow-up studies. Ann. Oncol. 25, 1901\u20131914 (2014).","journal-title":"Ann. Oncol."},{"key":"25043_CR19","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1007\/s10549-012-2073-x","volume":"134","author":"S Niraula","year":"2012","unstructured":"Niraula, S., Ocana, A., Ennis, M. & Goodwin, P. J. Body size and breast cancer prognosis in relation to hormone receptor and menopausal status: A meta-analysis. Breast Cancer Res. Treat. 134, 769\u2013781 (2012).","journal-title":"Breast Cancer Res. Treat."},{"key":"25043_CR20","doi-asserted-by":"crossref","unstructured":"Amin, M. B. et al. The eighth edition AJCC cancer staging manual: Continuing to build a bridge from a population-based to a more \u201cpersonalized\u201d approach to cancer staging. CA Cancer J. Clin. 67, 93\u201399 (2017).","DOI":"10.3322\/caac.21388"},{"key":"25043_CR21","doi-asserted-by":"publisher","first-page":"545","DOI":"10.5858\/arpa.2019-0904-SA","volume":"144","author":"KH Allison","year":"2020","unstructured":"Allison, K. H. et al. Estrogen and progesterone receptor testing in breast cancer: American society of clinical oncology\/college of American pathologists guideline update. Arch. Pathol. Lab. Med. 144, 545\u2013563 (2020).","journal-title":"Arch. Pathol. Lab. Med."},{"key":"25043_CR22","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1007\/s10549-010-0990-0","volume":"123","author":"M Protani","year":"2010","unstructured":"Protani, M., Coory, M. & Martin, J. H. Effect of obesity on survival of women with breast cancer: Systematic review and meta-analysis. Breast Cancer Res. Treat. 123, 627\u2013635 (2010).","journal-title":"Breast Cancer Res. Treat."},{"key":"25043_CR23","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41523-019-0128-4","volume":"5","author":"CK Blair","year":"2019","unstructured":"Blair, C. K. et al. Obesity and survival among a cohort of breast cancer patients is partially mediated by tumor characteristics. npj Breast Cancer 5, 1\u20137 (2019).","journal-title":"npj Breast Cancer"},{"key":"25043_CR24","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1007\/s10549-017-4507-y","volume":"167","author":"YL Liu","year":"2018","unstructured":"Liu, Y. L. et al. Obesity and survival in the neoadjuvant breast cancer setting: Role of tumor subtype in an ethnically diverse population. Breast Cancer Res. Treat. 167, 277\u2013288 (2018).","journal-title":"Breast Cancer Res. Treat."},{"key":"25043_CR25","doi-asserted-by":"publisher","first-page":"4203","DOI":"10.1200\/JCO.2016.68.4480","volume":"34","author":"S Jiralerspong","year":"2016","unstructured":"Jiralerspong, S. & Goodwin, P. J. Obesity and breast cancer prognosis: Evidence, challenges, and opportunities. J. Clin. Oncol. 34, 4203\u20134216 (2016).","journal-title":"J. Clin. Oncol."},{"key":"25043_CR26","unstructured":"OECD Health Division New. Obesity Update OECD. (2014)."},{"key":"25043_CR27","doi-asserted-by":"publisher","first-page":"2037","DOI":"10.1200\/JCO.21.00471","volume":"39","author":"JJ Griggs","year":"2021","unstructured":"Griggs, J. J. et al. Appropriate systemic therapy dosing for obese adult patients with cancer: ASCO guideline update. J. Clin. Oncol. 39, 2037\u20132048 (2021).","journal-title":"J. Clin. Oncol."},{"key":"25043_CR28","doi-asserted-by":"publisher","first-page":"903","DOI":"10.1007\/s10549-021-06137-3","volume":"187","author":"J O\u2019Shaughnessy","year":"2021","unstructured":"O\u2019Shaughnessy, J. et al. Recurrence rates in patients with HER2+ breast cancer who achieved a pathological complete response after neoadjuvant pertuzumab plus trastuzumab followed by adjuvant trastuzumab: A real-world evidence study. Breast Cancer Res. Treat. 187, 903\u2013913 (2021).","journal-title":"Breast Cancer Res. Treat."},{"key":"25043_CR29","doi-asserted-by":"crossref","unstructured":"Huober, J. et al. Abstract P2-08-01: Factors predicting relapse in early breast cancer patients with a pathological complete response after neoadjuvant therapy\u2014Results of a pooled analysis based on the GBG meta-database. in Cancer Research. Vol. 79. P2-08-01\u2013P2-08-01 (American Association for Cancer Research, 2019).","DOI":"10.1158\/1538-7445.SABCS18-P2-08-01"},{"key":"25043_CR30","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1002\/ijc.10209","volume":"98","author":"Y Cui","year":"2002","unstructured":"Cui, Y. et al. Body mass and stage of breast cancer at diagnosis. Int. J. Cancer 98, 279\u2013283 (2002).","journal-title":"Int. J. Cancer"},{"key":"25043_CR31","first-page":"365","volume":"104","author":"R Cruz-Coke","year":"1976","unstructured":"Cruz-Coke, R. Or\u00edgen y evoluci\u00f3n \u00e9tnica de la poblaci\u00f3n chilena. Rev. Med. Chil. 104, 365\u2013368 (1976).","journal-title":"Rev. Med. Chil."},{"key":"25043_CR32","doi-asserted-by":"publisher","first-page":"3411","DOI":"10.3390\/cancers14143411","volume":"14","author":"IS Jabbal","year":"2022","unstructured":"Jabbal, I. S. et al. Disparities in metabolic conditions and cancer characteristics among Hispanic women with breast cancer: A multi-institutional study. Cancers (Basel) 14, 3411 (2022).","journal-title":"Cancers (Basel)"},{"key":"25043_CR33","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1634\/theoncologist.2012-0373","volume":"18","author":"N Justo","year":"2013","unstructured":"Justo, N., Wilking, N., J\u00f6nsson, B., Luciani, S. & Cazap, E. A review of breast cancer care and outcomes in Latin America. Oncologist 18, 248\u2013256 (2013).","journal-title":"Oncologist"},{"key":"25043_CR34","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0224012","volume":"14","author":"LLP De Lemos","year":"2019","unstructured":"De Lemos, L. L. P. et al. Stage at diagnosis and stage-specific survival of breast cancer in Latin America and the Caribbean: A systematic review and metaanalysis. PLoS ONE 14, e0224012 (2019).","journal-title":"PLoS ONE"},{"key":"25043_CR35","doi-asserted-by":"publisher","first-page":"1669","DOI":"10.1016\/j.clnu.2020.10.037","volume":"40","author":"M Sadeghian","year":"2021","unstructured":"Sadeghian, M., Rahmani, S., Khalesi, S. & Hejazi, E. A review of fasting effects on the response of cancer to chemotherapy. Clin. Nutr. 40, 1669\u20131681 (2021).","journal-title":"Clin. Nutr."},{"key":"25043_CR36","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1159\/000510839","volume":"65","author":"F Plotti","year":"2020","unstructured":"Plotti, F. et al. Diet and chemotherapy: The effects of fasting and ketogenic diet on cancer treatment. Chemotherapy 65, 77\u201384 (2020).","journal-title":"Chemotherapy"},{"key":"25043_CR37","doi-asserted-by":"publisher","first-page":"650","DOI":"10.18632\/oncotarget.27453","volume":"11","author":"L Koniali","year":"2020","unstructured":"Koniali, L. et al. Risk factors for breast cancer brain metastases: A systematic review. Oncotarget 11, 650\u2013669 (2020).","journal-title":"Oncotarget"},{"key":"25043_CR38","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1007\/s10549-012-2243-x","volume":"136","author":"ND Arvold","year":"2012","unstructured":"Arvold, N. D. et al. Brain metastases after breast-conserving therapy and systemic therapy: Incidence and characteristics by biologic subtype. Breast Cancer Res. Treat. 136, 153\u2013160 (2012).","journal-title":"Breast Cancer Res. Treat."},{"key":"25043_CR39","doi-asserted-by":"publisher","first-page":"921","DOI":"10.1208\/s12248-017-0079-3","volume":"19","author":"EM Rhea","year":"2017","unstructured":"Rhea, E. M. et al. Blood-brain barriers in obesity. AAPS J. 19, 921\u2013930 (2017).","journal-title":"AAPS J."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-25043-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-25043-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-25043-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,7]],"date-time":"2022-12-07T11:15:27Z","timestamp":1670411727000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-25043-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12,7]]},"references-count":39,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["25043"],"URL":"https:\/\/doi.org\/10.1038\/s41598-022-25043-2","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,12,7]]},"assertion":[{"value":"25 January 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 November 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 December 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"21145"}}